Binh Dinh Pharmaceutical and Medical Equipment JSC (Bidiphar) inaugurated its anti-cancer drug manufacturing plant in Binh Dinh Province, south-central Vietnam on Saturday.
The facility spans an area of 1.5 hectares in the Nhon Hoi Economic Zone in the provincial capital city of Quy Nhon, with a total investment of more than VND500 billion (US$20.5 million).
The Bidiphar plant, whose work started in August 2018, is expected to churn out three million anti-cancer injections and 70 million cancer-fighting tablets per year, in line with the GMP-EU standards.
The European Medicines Agency’s good manufacturing practice (GMP) describes the minimum standard that a medicine manufacturer must meet in their production processes.
The facility is outfitted with fully-automated, self-contained equipment. It is configured to produce over 10 types of drugs that have undergone a successful study and are currently undergoing an appraisal process before seeking approval from the Health Ministry for circulation.
During the inauguration ceremony, Deputy Minister of Health Do Xuan Tuyen commended Bidiphar for their endeavors in researching and developing drugs. He highlighted the use of advanced technologies in the manufacturing process, aiming to replace current cancer treatment drugs that are typically imported.
The establishment of the plant will enable Vietnam's healthcare sector to consistently secure high-quality drug supplies at reasonable prices for patient treatment, as stated by the senior health official.
Bidiphar's general director, Pham Thi Thanh Huong, revealed that the company collaborated with institutes and universities to successfully research and develop more than 40 cancer drugs featuring 17 active ingredients. These drugs have received approval from the health ministry for circulation.
Bidiphar on the same day broke ground on a project to build a small-volume aseptic drug manufacturing plant adhering to GMP-EU standards.
This facility, spanning over 25,000 square meters in Binh Dinh, is projected to cost VND840 billion ($34.5 million) and is scheduled to commence operations in 2027.